In late March, Boehringer Ingelheim GMBH formally unveiled its $134 million corporate venture fund, a strategically focused effort that will invest in areas believed to be important to the privately held German pharma's future growth, including RNA silencing, stem cells, and next-generation vaccine, protein, and antibody technologies.
It's a small piece of good news for early-stage biotechs and their venture backers, who continue to endure one of...







